Hospital
Aurora Health Care Southern Lakes, INC.
Aurora Health Care Southern Lakes, INC. was paid $7.12M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 13% of everything it billed.
33Billing provider infoAURORA HEALTH CARE SOUTHERN LAKES, INC.
ELKHORN, WI 53121
ELKHORN, WI 53121
33aNPI1972628006assigned 03/20/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.12M
24GClaims287,876
24DCodes billed154
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#20 of 60
Median peer was paid$2.90M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,950 | $947K | |
| 2019 | 35,154 | $925K | |
| 2020 | 32,586 | $849K | |
| 2021 | 44,985 | $1.04M | |
| 2022 | 46,492 | $1.07M | |
| 2023 | 52,530 | $1.25M | |
| 2024incomplete | 39,179 | $1.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 26,364 | 8,434 | $891K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 12,351 | 11,143 | $772K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.4% | 4,687 | 4,014 | $670K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.4% | 10,873 | 9,654 | $598K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 7,032 | 6,182 | $389K |
| 80053 | Comprehensive metabolic panel | 4.2% | 14,066 | 11,480 | $296K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 4.0% | 13,370 | 4,836 | $284K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 3,527 | 3,229 | $230K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 2,708 | 2,495 | $207K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 2,863 | 2,611 | $193K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.6% | 7,428 | 4,303 | $183K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.5% | 1,721 | 1,482 | $174K |
142 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 3,080 | $171K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 16,387 | $106K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 2,630 | $105K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,525 | $90K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 2,164 | $90K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 900 | $89K |
| 97161 | 1.2% | 2,043 | $88K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.1% | 3,567 | $82K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 1,795 | $79K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 776 | $61K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 874 | $56K |
| 97162 | <1% | 1,607 | $55K | |
| 82077 | <1% | 2,013 | $55K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,693 | $51K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 732 | $51K |
| 84484 | <1% | 4,788 | $51K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 948 | $50K |
| 81025 | <1% | 4,373 | $42K | |
| 76801 | <1% | 806 | $41K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,043 | $36K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 144 | $35K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 866 | $34K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 754 | $33K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 367 | $32K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 273 | $30K |
| 83735 | <1% | 5,689 | $28K | |
| 83880 | <1% | 873 | $27K | |
| 76830 | Ultrasound, transvaginal | <1% | 701 | $26K |
| 83690 | <1% | 4,234 | $25K | |
| 83605 | <1% | 2,793 | $25K | |
| 84145 | <1% | 1,195 | $22K | |
| 81001 | <1% | 5,284 | $21K | |
| 82962 | <1% | 2,616 | $20K | |
| G0378 | Hospital observation service, per hour | <1% | 1,064 | $18K |
| 93356 | <1% | 190 | $18K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 233 | $17K |
| 81003 | <1% | 2,893 | $17K | |
| 80143 | <1% | 1,319 | $16K | |
| 80179 | <1% | 1,304 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 392 | $16K |
| 97035 | <1% | 1,292 | $16K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 57 | $16K |
| 93975 | <1% | 427 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,133 | $14K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 409 | $13K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 188 | $13K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 208 | $12K |
| 87040 | <1% | 1,017 | $12K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,019 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 447 | $12K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 222 | $11K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 166 | $11K |
| 85379 | <1% | 1,408 | $11K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 31 | $10K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 107 | $10K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 804 | $9K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 89 | $9K |
| 85610 | <1% | 2,559 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,730 | $8K |
| 87081 | <1% | 222 | $7K | |
| 85730 | <1% | 1,389 | $6K | |
| 71250 | <1% | 193 | $5K | |
| 87077 | <1% | 357 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,797 | $4K |
| 86850 | <1% | 256 | $4K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 38 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 260 | $4K |
| 86900 | <1% | 418 | $4K | |
| 87186 | <1% | 395 | $3K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 66 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,527 | $2K |
| 97116 | <1% | 173 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 216 | $2K |
| 0240U | <1% | 65 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,643 | $2K |
| 93971 | <1% | 30 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 325 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 38 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 38 | $1K |
| 82565 | <1% | 90 | $1K | |
| 84112 | <1% | 15 | $1K | |
| 97597 | <1% | 38 | $1K | |
| 97165 | <1% | 30 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 21 | $1K |
| 86901 | <1% | 418 | $1K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 103 | $919.96 |
| 85027 | <1% | 103 | $909.17 | |
| 84702 | <1% | 28 | $829.44 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,014 | $670.88 |
| 93017 | <1% | 14 | $471.39 | |
| 0399T | <1% | 16 | $441.57 | |
| 73630 | <1% | 107 | $423.44 | |
| 82550 | <1% | 82 | $416.30 | |
| 87088 | <1% | 54 | $364.52 | |
| 86140 | <1% | 100 | $344.28 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 15 | $307.86 |
| 94060 | <1% | 13 | $296.60 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 85 | $231.61 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,878 | $177.38 |
| 87807 | <1% | 17 | $151.80 | |
| 85652 | <1% | 62 | $132.02 | |
| 87210 | <1% | 14 | $72.60 | |
| 73030 | <1% | 27 | $63.21 | |
| 73610 | <1% | 44 | $56.15 | |
| 73562 | <1% | 13 | $47.99 | |
| 73130 | <1% | 15 | $37.74 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,448 | $17.43 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 495 | $17.27 |
| 74018 | <1% | 15 | $16.00 | |
| 96376 | <1% | 750 | $14.36 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,770 | $6.51 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $4.32 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,798 | $3.07 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,006 | $2.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,118 | $2.78 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 396 | $2.69 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,583 | $2.64 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 553 | $0.74 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,272 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 288 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 1,052 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,330 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,939 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,421 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 513 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 877 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 40 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 148 | $0.00 |
| 80320 | 0% | 51 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 93 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 4,780 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,089 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 314 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 163 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,098 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 241 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 27 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 25 | $0.00 |
| 94726 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 22 | $0.00 |
| 94729 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.